# Peptide Protocol Monitoring

**Schedule:** Baseline → Week 8 → Week 16

---

## Bloodwork Panel

| Test | Target | Reason |
|------|--------|--------|
| Fasting Glucose | <100 mg/dL | GH, Acarbose, Metformin |
| Fasting Insulin | Low-normal | GH-induced insulin resistance |
| HbA1c | <5.7% | 3-month glucose average |
| IGF-1 | 150-250 ng/mL | GH compound dosing |
| ALT, AST, GGT | <2x upper limit | Hepatic clearance |
| Creatinine, eGFR | eGFR >60 | Renal clearance; <30 contraindicated |
| CBC + Differential | Normal; Haematocrit <52% | Baseline; infections on Rapamycin; polycythaemia |
| Lipid Panel | Stable/improving | CV risk |
| ApoB | <65 mg/dL | Atherogenic particles; Repatha target |
| Lp(a) | Baseline only | Genetic CV risk (one-time) |
| TSH, Free T3, Free T4 | Mid-range | GH affects thyroid axis |
| Total Testosterone | M: 500-900 ng/dL | TRT efficacy (trough level) |
| Free Testosterone | Upper quartile | Bioavailable T |
| Oestradiol (sensitive) | M: 20-35 pg/mL | Aromatisation |
| SHBG | Context-dependent | Interprets free hormones |
| Prolactin | Normal | Cabergoline monitoring (Athena only) |
| PSA (M >40) | <4.0; stable | Oncogenic risk — growth factors |
| CEA | <3.0 ng/mL | Oncogenic risk — growth factors |
| CA-125 (F) | <35 U/mL | Oncogenic risk — growth factors |
| Ferritin | M: 50-150 / F: 50-100 | Iron stores |
| Vitamin B12 | >400 pg/mL | Metformin depletion |
| Vitamin D | 50-80 ng/mL | Bone, immune |

**Note (F):** Test Oestradiol day 3-5 of cycle for consistency

---

## Safety Stop Rules

### IGF-1 (GH Compounds)
| Level | Action |
|-------|--------|
| >300 ng/mL (or Z-score >2) | Reduce GH compound dose by 50% |
| >400 ng/mL (or Z-score >3) | **Discontinue all GH compounds** |

### HbA1c (Metabolic)
| Level | Action |
|-------|--------|
| Increase >0.5% from baseline | Initiate Metformin 500mg BID (or Berberine) |
| >5.7% | Initiate Metformin; reassess protocol |

### Tumor Markers (Oncogenic Risk)
| Finding | Action |
|---------|--------|
| **Any elevation in PSA, CEA, or CA-125** | **Immediate cessation of all growth factors** |

**Growth factors to stop:** Tesamorelin, HGH, BPC-157, TB-500, GHK-Cu, Follistatin

### Haematocrit (Men on TRT + GH)
| Level | Action |
|-------|--------|
| >52% | Reduce GH/TRT doses; hydrate; consider phlebotomy |
| >54% | **Stop protocol; urgent medical review** |

### Other Stops
| Finding | Action |
|---------|--------|
| Liver enzymes >3x upper limit | Stop protocol |
| PSA increase >0.75 ng/mL/year | Urology referral; hold growth factors |
| eGFR <30 | Protocol contraindicated |

---

## Compound-Specific Monitoring

| Compound | Protocol | Monitor |
|----------|----------|---------|
| Rapamycin | All | Mouth sores, infections, wound healing |
| LDN | Prometheus | **No opioids** — precipitates withdrawal |
| Aspirin | Prometheus | GI bleeding (dark stools); uric acid |
| Acarbose | Prometheus | GI effects; glucose tablets for hypo (not sucrose) |
| 17-alpha Estradiol | Prometheus (M) | Oestradiol stable; no feminisation |
| Cabergoline | Athena | Prolactin; cardiac echo if >12 months |
| PT-141 | Athena | BP (transient increase); nausea |
| Kisspeptin | Athena | Cycle timing; may shift ovulation |
| Teriparatide | Athena | Serum calcium; DEXA; max 2 years |
| Follistatin-344 | Titan | Cardiac symptoms; 10-14 day courses |
| Dihexa | Titan | Mood, cognition, sleep; cycle 4-6 weeks |
| TB-500 | Titan | Cancer screening current; no malignancy history |

---

## Pre-Procedure Holds

| Compound | Hold |
|----------|------|
| Metformin | 48h before/after IV contrast |
| Rapamycin | 1-2 weeks before surgery |
| LDN | 3-5 days before surgery |
| Aspirin | 7 days before surgery |

---

## Advanced Longevity (Optional)

| Test | Purpose |
|------|---------|
| Cystatin C | More accurate renal function (not affected by muscle mass) |
| Biological Age (TruDiagnostic/GlycanAge) | Protocol efficacy |
| Telomere Length | Pre/post Epithalon |
| DUTCH Complete | Hormone metabolites |
| GDF-15 | Aging marker |
| DEXA Scan | Bone density (women) |
| Coronary Calcium Score | CV aging |
